Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 17, 2015– AVEO Oncology (NASDAQ:AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody (the “Product”). Under the terms of the agreement, AVEO will receive

Download PDF Company to Host Midyear Update Conference Call Today, August 10 at 10:00 am ET CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 10, 2015– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2015. “The second quarter was productive on multiple fronts for AVEO, including clinical updates, regulatory guidance and another partnership for tivozanib, in addition to completion of our

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 5, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into an exclusive license agreement with a subsidiary of Pharmstandard Group, the largest Russian pharmaceutical group (“Pharmstandard”), for the development, manufacturing and commercialization of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor tivozanib in the territories of Russia, Ukraine and the Commonwealth

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 5, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call on Monday, August 10, 2015, at 10:00 a.m. Eastern Time to provide an update on recent developments and corporate goals, as well as discuss financial results for the second quarter ended June 30, 2015. The call can be accessed by dialing 1-866-428-2694

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 30, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that additional biomarker analyses from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study will be presented at the European Society for Medical Oncology (ESMO) 17thWorld Congress on Gastrointestinal Cancer, taking place July 1-4 in Barcelona, Spain. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 11, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a long half-life and

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 3, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that, following pre-submission advisory meetings to discuss the potential submission of a Marketing Authorization Application (MAA) for tivozanib in Europe for the treatment of renal cell carcinoma (RCC), it has received written confirmation of support from the Rapporteur and co-Rapporteur for the filing of such an application.

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 29, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 8:00 AM (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at www.aveooncology.com. A